Market closed
Merus/$MRUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
291
Website
Merus Metrics
BasicAdvanced
$3.1B
-
-$3.35
1.15
-
Price and volume
Market cap
$3.1B
Beta
1.15
52-week high
$61.61
52-week low
$33.19
Average daily volume
814K
Financial strength
Current ratio
6.535
Quick ratio
6.221
Long term debt to equity
1.267
Total debt to equity
1.53
Management effectiveness
Return on assets (TTM)
-27.47%
Return on equity (TTM)
-42.88%
Valuation
Price to revenue (TTM)
80.78
Price to book
4.83
Price to tangible book (TTM)
4.84
Price to free cash flow (TTM)
-15.553
Growth
Revenue change (TTM)
-17.78%
Earnings per share change (TTM)
11.67%
3-year revenue growth (CAGR)
-9.72%
3-year earnings per share growth (CAGR)
24.70%
What the Analysts think about Merus
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Merus Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Merus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Merus News
AllArticlesVideos
Merus: Riding The Bispecific Wave In Oncology
Seeking Alpha·4 weeks ago
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·1 month ago
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $3.1B as of May 03, 2025.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of May 03, 2025.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.